PR Newswire CHENGDU, China, Feb. 7, 2025 CHENGDU, China, Feb. 7, 2025 /PRNewswire/ -- KeyMed Biosciences (HKEX: 02162) today announced the National Medical Products Administration (the "NMPA") of China has recently approved the supplemental ...
PR Newswire NORTH CHICAGO, Ill., Feb. 7, 2025 NORTH CHICAGO, Ill., Feb. 7, 2025 /PRNewswire/ -- AbbVie (NYSE: ABBV) today announced that the U.S. Food and Drug Administration (FDA) has approved EMBLAVEO™ (aztreonam and avibactam), as the ...
Canada NewsWire MONTREAL, Feb. 7, 2025 MONTREAL, Feb. 7, 2025 /CNW/ - Pharmascience Canada is proud to announce the launch of Pr pms-RUPATADINE (rupatadine), a treatment that helps relieve nasal and non-nasal symptoms of seasonal allergic ...
PR Newswire COPENHAGEN, Denmark and CAMBRIDGE, Mass., Feb. 7, 2025 Interim results demonstrate treatment with HMB-001 resulted in >50% reduction in treated bleeds at all tested dose levels In second oral presentation, Hemab presented ...
PR Newswire SAN DIEGO, Feb. 7, 2025 Results provide clinical demonstration of best-in-class immunogenicity achieved with an RNA-based platform and good tolerability RBI-4000's potential to offer a meaningful improvement over existing ...
PR Newswire INDIANAPOLIS, Feb. 7, 2025 More than 90% of Omvoh-treated patients who were in clinical remission at one year sustained it with two years of continuous treatment Nearly 90% of patients who achieved endoscopic response at one ...
PR Newswire HONG KONG, Feb. 5, 2025 HONG KONG, Feb. 5, 2025 /PRNewswire/ -- Akeso, Inc. (9926.HK) ("Akeso" or the "Company") is excited to announce the completion of patient enrollment in the global Phase III clinical trial ...
PR Newswire BOSTON and LAUSANNE, Switzerland, Feb. 4, 2025 BOSTON and LAUSANNE, Switzerland, Feb. 4, 2025 /PRNewswire/ -- Alys Pharmaceuticals, Inc. ("Alys"), an immune-dermatology focused company, today announces that the U.S. Food and Drug ...
PR Newswire STOCKHOLM, Jan. 31, 2025 STOCKHOLM, Jan. 31, 2025 /PRNewswire/ -- BioArctic AB's (publ) (Nasdaq Stockholm: BIOA B) partner Eisai today announced that the European Commission has asked the Committee for Medicinal Products for ...
PR Newswire JERSEY CITY, N.J., Jan. 30, 2025 JERSEY CITY, N.J., Jan. 30, 2025 /PRNewswire/ -- Celltrion today announced that the U.S. Food and Drug Administration (FDA) has approved AVTOZMA® (CT-P47, tocilizumab-anoh) in both an intravenous ...
Lecanemab use is higher among white, male, urban, and wealthier patients despite broad Medicare coverage.
New antifungal nanotechnology uses targeted liposomes to boost drug delivery and fight Candida infections.
Real-world evidence shows long-term use of oral and inhaled steroids increases the risk of adrenal insufficiency, highlighting the need for proper treatment alternatives.
Legalizing and increased consumption of cannabis has led to increased cases of people visiting hospitals, many due to anxiety, psychosis, and other mental health disorders.
Glucagon-like peptide-1 receptor agonists improve cardiovascular outcomes and reduce mortality in patients with type 2 diabetes.
Subscribe to our Free Newsletters!
Medindia's policies are aligned with the United Nations Sustainable Development Goals (SDGs) - SDG 3, SDG 4, SDG 5, SDG 6 , SDG 10 & SDG 12.
Disclaimer - All information and content on this site are provided for informational and educational purposes only. They should NOT be used for the diagnosis or treatment of any health-related condition or disease. Always consult a qualified healthcare professional for medical advice, diagnosis, or treatment. Full Disclaimer
Advertise with us | Medindia Copyright | Privacy Policy | Terms of Use © All Rights Reserved 1997 - 2025
Careers